Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 276 to 292 of 292

Type: GuidanceRemove Type: Guidance filter
Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter
Guidance programme: Highly specialised technologies guidanceRemove Guidance programme: Highly specialised technologies guidance filter

Guidance and quality standards awaiting development
Title	Type
Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]	Technology appraisal guidance
Vilobelimab for treating COVID 19 [TSID11815]	Technology appraisal guidance
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]	Technology appraisal guidance
WP1048 for treating grass pollen allergy in people aged 18 to 60 [TSID10467]	Technology appraisal guidance
Xanomeline tartrate–trospium chloride for treating schizophrenia [TSID12311]	Technology appraisal guidance
Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity [TSID11902]	Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies [TSID10765]	Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable [TSID10477]	Technology appraisal guidance
Zanidatamab with chemotherapy with or without tislelizumab for untreated HER2-positive unresectable advanced gastro-oesophageal adenocarcinoma [ID6672]	Technology appraisal guidance
Zanubrutinib with rituximab for untreated mantle cell lymphoma when a stem cell transplant is unsuitable [ID6641]	Technology appraisal guidance
Zasocitinib for treating moderate to severe plaque psoriasis [ID6700]	Technology appraisal guidance
Zavegepant for treating acute migraine [TSID11998]	Technology appraisal guidance
Zilurgisertib for preventing new heterotopic ossification lesions caused by fibrodysplasia ossificans progressiva in people 12 years and over [ID6637]	Technology appraisal guidance
Zimislecel for treating type 1 diabetes in people 12 years and over with impaired hypoglycaemic awareness and severe hypoglycaemia [ID6624]	Technology appraisal guidance
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]	Technology appraisal guidance
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [TSID12040]	Technology appraisal guidance
Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573]	Technology appraisal guidance

Results per page

10
25
50
All